Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb has entered into a collaboration agreement with The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as part of the company's Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the US.
Subscribe to our email newsletter
The I-O RPM research program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.
As part of the I-O RPM program, Bristol-Myers Squibb and the Johns Hopkins Kimmel Cancer Center will conduct a range of early phase clinical studies and Bristol-Myers Squibb will fund positions within The Johns Hopkins University School of Medicine fellowship program.
Bristol-Myers Squibb head of US Medical Laura Bessen said: "Johns Hopkins has been a long-time collaborator with Bristol-Myers Squibb in immuno-oncology research.
"We look forward to working with them as part of the I-O RPM research program as we continue to advance the science in this innovative field of cancer research and development, particularly among subpopulations of patients with high risk, poor prognostic cancers."
About I-O RPM
Immuno-oncology is an innovative approach to cancer research and treatment that is designed to harness the body’s own immune system to fight cancer. The I-O RPM research program focuses on significant areas of high unmet need marked by poor outcomes among patients with rare population malignancies.
A rare population malignancy is a subpopulation within a higher incident disease population. These patients have aggressive disease with an increased potential for early metastasis to multiple sites and/or are initially refractory or subject to early recurrences with conventional cancer therapies. Existing clinical research provide a strong rationale for further research into the potential of immunotherapies for these cancers.
The I-O RPM research program is a multi-institutional initiative with Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute, Moffitt Cancer Center and now the Johns Hopkins Kimmel Cancer Center.
I-O RPM builds on Bristol-Myers Squibb’s formation in 2012 of the International Immuno-Oncology Network (II-ON), which is a global collaboration between Bristol-Myers Squibb and academia focused on facilitating the translation of scientific research findings into clinical trials and, eventually, clinical practice.